IL17A and metabolic dysfunction-associated steatotic liver disease: Further, IL-17- and inflammatory pathways such as, those in non-alcoholic fatty liver disease (NAFLD), AGE-RAGE signaling and NFκβ pathways were upregulated (Fig. 2b).